Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa

Affiliations

¹ Lung Infection and Immunity Unit, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: keertan.dheda@uct.ac.za.
² Lung Infection and Immunity Unit, Department of Medicine, University of Cape Town, Cape Town, South Africa; Institute of Infectious Diseases and Molecular Medicine, Cape Town, South Africa.
³ South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa.

Free article

Comment

Keertan Dheda et al. Lancet Glob Health. 2014 Oct.

Free article

. 2014 Oct;2(10):e554-6.

doi: 10.1016/S2214-109X(14)70305-5.

¹ Lung Infection and Immunity Unit, Department of Medicine, University of Cape Town, Cape Town, South Africa. Electronic address: keertan.dheda@uct.ac.za.
² Lung Infection and Immunity Unit, Department of Medicine, University of Cape Town, Cape Town, South Africa; Institute of Infectious Diseases and Molecular Medicine, Cape Town, South Africa.
³ South African Centre for Epidemiological Modelling and Analysis, Stellenbosch University, Stellenbosch, South Africa.

No abstract available

Comment in

Cost-effectiveness of Xpert MTB/RIF and investing in health care in Africa.
Langley I, Lin HH, Squire SB. Langley I, et al. Lancet Glob Health. 2015 Feb;3(2):e83-4. doi: 10.1016/S2214-109X(14)70370-5. Lancet Glob Health. 2015. PMID: 25617201 No abstract available.

Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach.
Langley I, Lin HH, Egwaga S, Doulla B, Ku CC, Murray M, Cohen T, Squire SB. Langley I, et al. Lancet Glob Health. 2014 Oct;2(10):e581-91. doi: 10.1016/S2214-109X(14)70291-8. Lancet Glob Health. 2014. PMID: 25304634